Page last updated: 2024-12-06

2,5-dihydroxybenzaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,5-Dihydroxybenzaldehyde, also known as 2,5-DHB, is a naturally occurring organic compound found in various plants. It is a white to yellowish crystalline solid with a distinctive odor. 2,5-DHB has been shown to possess antioxidant and antimicrobial properties. It is also an important intermediate in the synthesis of various pharmaceuticals and agrochemicals. Research on 2,5-DHB focuses on its potential applications in medicine, agriculture, and environmental protection. The compound's ability to scavenge free radicals and inhibit microbial growth has attracted significant interest. Its synthesis typically involves the oxidation of 2,5-dihydroxytoluene or the reduction of 2,5-dihydroxybenzoic acid. Ongoing research aims to explore the biological activity of 2,5-DHB and its derivatives, particularly in relation to their potential for treating various diseases.'

2,5-dihydroxybenzaldehyde: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,5-dihydroxybenzaldehyde : A dihydroxybenzaldehyde carrying hydroxy groups at positions 2 and 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID70949
CHEMBL ID243186
CHEBI ID28508
SCHEMBL ID36835
MeSH IDM0291524

Synonyms (50)

Synonym
AC-12258
NCIOPEN2_000629
2,5-dhbaop
gentisaldehyde
benzaldehyde,5-dihydroxy-
nsc-72387
1194-98-5
nsc72387
CHEBI:28508 ,
inchi=1/c7h6o3/c8-4-5-3-6(9)1-2-7(5)10/h1-4,9-10
benzaldehyde, 2,5-dihydroxy-
C05585
2,5-dihydroxybenzaldehyde
gentisate aldehyde
2,5-dihydroxybenzaldehyde, 98%
4991335E-F710-4A4F-927E-62D82076133E
D0565
gentisinaldehyde
AKOS000112412
CHEMBL243186 ,
einecs 214-789-6
0q83hds90w ,
unii-0q83hds90w
nsc 72387
BMSE000962
FT-0610381
PS-4073
dihydroxybenzaldehyde, 2,5-
formylhydroquinone
5-hydroxysalicylaldehyde
2,5-dihydroxy benzaldehyde
2,5-dihydroxy-benzaldehyde
2,5 dihydroxybenzaldehyde
SCHEMBL36835
DTXSID1061601
J-200040
mfcd00003333
bdbm50478478
H11349
2,5-dihydroxybenzaldehyde, vetec(tm) reagent grade, 98%
SY011437
benzaldehyde, 2,5-dihydroxy-;gentisaldehyde;gentisate aldehyde
BCP26028
Q27103744
CS-0017335
AMY432
HY-N1673
A892551
EN300-49273
Z586251264
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Penicillium metaboliteAny fungal metabolite produced during a metabolic reaction in Penicillium.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dihydroxybenzaldehydeAny member of the class of benzaldehydes in which the phenyl ring is substituted by two hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
patulin biosynthesis532

Bioassays (16)

Assay IDTitleYearJournalArticle
AID337238Inhibition of mouse EGFR by liquid scintillation counting
AID1337095Inhibition of human MPO2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
From Dynamic Combinatorial Chemistry to
AID1291721Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion by measuring minimal hemolytic dose administered immediately after venom injection measured after 24 hrs (Rvb =5 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID293934Inhibition of pieris rapae Phenoloxidase2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
3D-QSAR and molecular docking studies of benzaldehyde thiosemicarbazone, benzaldehyde, benzoic acid, and their derivatives as phenoloxidase inhibitors.
AID1291712Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291717Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.28ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1186380Antileishmanial activity against promastigote forms of Leishmania donovani by alamar blue assay2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Antileishmanial metabolites from Geosmithia langdonii.
AID1291710Protective activity against Daboia russellii venom-induced mortality by measuring venom LD50 in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs (Rvb = 2.28 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291715Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative t2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291719Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv by measuring venom LD50 administered immediately after venom injection measured after 24 hrs (Rvb = 2.82 ug)2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291718Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291716Lipophilicity, log P of compound2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291711Protective activity against Daboia russellii venom-induced mortality in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291714Protective activity against Daboia russellii venom-induced hemorrhage in intradermally dosed Swiss albino mouse at 100 mmol assessed as hemorhagic lesion by measuring minimal hemolytic dose preincubated with venom for 1 hr followed by administration to mo2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291713Protective activity against Naja kaouthia venom-induced mortality in Swiss albino mouse at 100 mmol, iv preincubated with venom for 1 hr followed by administration to mouse measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
AID1291722Protective activity against Daboia russellii venom-induced hemorrhage in Swiss albino mouse at 100 mmol, iv assessed as hemorhagic lesion administered immediately after venom injection measured after 24 hrs relative to untreated control2016European journal of medicinal chemistry, May-23, Volume: 114Molecular modeling and snake venom phospholipase A2 inhibition by phenolic compounds: Structure-activity relationship.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (13.33)18.2507
2000's2 (13.33)29.6817
2010's11 (73.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.86 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]